{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:13:52Z","timestamp":1764663232542,"version":"3.46.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41409-025-02709-9","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:30:25Z","timestamp":1757917825000},"page":"1592-1600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-6570","authenticated-orcid":false,"given":"Maxime","family":"Jullien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-9592","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Labussiere-Wallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Schmidt-Tanguy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Beckerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-8310","authenticated-orcid":false,"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-5180","authenticated-orcid":false,"given":"Jacques Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4187","authenticated-orcid":false,"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Alani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Souchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-5442","authenticated-orcid":false,"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude-Eric","family":"Bulabois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alban","family":"Villate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-6976","authenticated-orcid":false,"given":"Amandine","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-8565","authenticated-orcid":false,"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of The Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2709_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","volume":"59","author":"JR Passweg","year":"2024","unstructured":"Passweg JR, Baldomero H, Ciceri F, de la C\u00e1mara R, Glass B, Greco R, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transpl. 2024;59:803\u201312.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2709_CR3","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1172\/JCI128710","volume":"129","author":"V Radojcic","year":"2019","unstructured":"Radojcic V, Luznik L. Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Investig. 2019;129:2189\u201391.","journal-title":"J Clin Investig"},{"key":"2709_CR4","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbmt.2019.07.028","volume":"25","author":"LJ Arcuri","year":"2019","unstructured":"Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transpl. 2019;25:2422\u201330.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2709_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41409-023-02042-z","volume":"58","author":"MJ Rieger","year":"2023","unstructured":"Rieger MJ, Stolz SM, M\u00fcller AM, Schwotzer R, Nair G, Schneidawind D, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm. Bone Marrow Transpl. 2023;58:1121\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR6","doi-asserted-by":"publisher","first-page":"158.e1","DOI":"10.1016\/j.jtct.2021.11.009","volume":"28","author":"A Srinivasan","year":"2022","unstructured":"Srinivasan A, Raffa E, Wall DA, Schechter T, Ali M, Chopra Y, et al. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis. Transplant Cell Ther. 2022;28:158.e1\u2013158.e9.","journal-title":"Transplant Cell Ther"},{"key":"2709_CR7","doi-asserted-by":"publisher","first-page":"316.e1","DOI":"10.1016\/j.jtct.2023.10.021","volume":"30","author":"Y Nakaya","year":"2024","unstructured":"Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, et al. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transplant Cell Ther. 2024;30:316.e1\u2013316.e12.","journal-title":"Transplant Cell Ther"},{"key":"2709_CR8","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00277-023-05300-8","volume":"103","author":"LJ Arcuri","year":"2024","unstructured":"Arcuri LJ, Ribeiro AAF, Hamerschlak N, Kerbauy MN. Posttransplant cyclophosphamide beyond haploidentical transplantation. Ann Hematol. 2024;103:1483\u201391.","journal-title":"Ann Hematol"},{"key":"2709_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-139440","volume":"136","author":"S Harbi","year":"2020","unstructured":"Harbi S, Boher jeanM, Forcade E, Chevallier P, R\u00e9gis PDL, Malard F, et al. Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study. Blood. 2020;136:35\u201336.","journal-title":"Blood"},{"key":"2709_CR10","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.4081\/pr.2011.s2.e15","volume":"3","author":"A Munchel","year":"2011","unstructured":"Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep. 2011;3:e15.","journal-title":"Pediatr Rep."},{"key":"2709_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2332866","volume":"29","author":"J Sugita","year":"2024","unstructured":"Sugita J, Yanada M. Current status of conditioning regimens in haploidentical hematopoietic cell transplantation. Hematology. 2024;29:2332866.","journal-title":"Hematology"},{"key":"2709_CR12","doi-asserted-by":"publisher","first-page":"33528","DOI":"10.18632\/oncotarget.26083","volume":"9","author":"P Chevallier","year":"2018","unstructured":"Chevallier P, Peterlin P, Garnier A, Le Bourgeois A, Mah\u00e9 B, Dubruille V, et al. Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget. 2018;9:33528\u201335.","journal-title":"Oncotarget"},{"key":"2709_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","volume":"25","author":"R Dul\u00e9ry","year":"2019","unstructured":"Dul\u00e9ry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, et al. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:1407\u201315.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2709_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41409-023-01956-y","volume":"58","author":"M Jullien","year":"2023","unstructured":"Jullien M, Le Bourgeois A, Peterlin P, Garnier A, Guillaume T, B\u00e9n\u00e9 MC, et al. Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival. Bone Marrow Transpl. 2023;58:723\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clml.2020.04.003","volume":"20","author":"J El-Cheikh","year":"2020","unstructured":"El-Cheikh J, Devillier R, Dulery R, Massoud R, Al Chami F, Ghaoui N, et al. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2020;20:617\u201323.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2709_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41409-022-01674-x","volume":"57","author":"R Devillier","year":"2022","unstructured":"Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AM, Pavlu J, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transpl. 2022;57:1421\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP\u2013EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"2709_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2709_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2709_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"Journal Am Stat Assoc"},{"key":"2709_CR22","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2709_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2709_CR24","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"2709_CR25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","volume":"25","author":"T Pagliardini","year":"2019","unstructured":"Pagliardini T, Castagna L, Harbi S, Porta MD, Rey J, F\u00fcrst S, et al. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Biol Blood Marrow Transpl. 2019;25:1803\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2709_CR26","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1097\/HS9.0000000000000952","volume":"7","author":"F Saraceni","year":"2023","unstructured":"Saraceni F, Labopin M, Raiola AM, Blaise D, Rem\u00e9nyi P, Sor\u00e0 F, et al. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7:e952.","journal-title":"Hemasphere"},{"key":"2709_CR27","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Rem\u00e9nyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28\u201339.","journal-title":"Lancet Haematol"},{"key":"2709_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41409-023-02023-2","volume":"58","author":"G Cassanello","year":"2023","unstructured":"Cassanello G, Serpenti F, Bagnoli F, Saporiti G, Goldaniga M, Cavallaro F, et al. Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience. Bone Marrow Transpl. 2023;58:1059\u201361.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","volume":"58","author":"R Dul\u00e9ry","year":"2023","unstructured":"Dul\u00e9ry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transpl. 2023;58:1215\u201322.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR30","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/bloodadvances.2023011759","volume":"8","author":"AM Raiola","year":"2024","unstructured":"Raiola AM, Di Grazia C, Dominietto A, Bregante S, Giammarco S, Varaldo R, et al. Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up. Blood Adv. 2024;8:1964\u20137.","journal-title":"Blood Adv"},{"key":"2709_CR31","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.4049\/jimmunol.2000578","volume":"205","author":"DR Makanga","year":"2020","unstructured":"Makanga DR, Guillaume T, Willem C, Legrand N, Gagne K, Cesbron A, et al. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. J Immunol. 2020;205:1441\u20138.","journal-title":"J Immunol"},{"key":"2709_CR32","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","volume":"18","author":"JR Passweg","year":"2004","unstructured":"Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, K\u00fchne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835\u20138.","journal-title":"Leukemia"},{"key":"2709_CR33","unstructured":"Prin Felix L Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies. ASH, 2024 https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper203266.html (accessed 6 Dec2024)."},{"key":"2709_CR34","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1097\/MPH.0000000000001222","volume":"40","author":"A Sharma","year":"2018","unstructured":"Sharma A, Kang G, Sunkara A, Inaba H, Jeha S, Cross SJ, et al. Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. J Pediatr Hematol Oncol. 2018;40:e479\u201385.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2709_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41409-022-01839-8","volume":"58","author":"N Santoro","year":"2023","unstructured":"Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, et al. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transpl. 2023;58:54\u201360.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR36","doi-asserted-by":"publisher","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","volume":"27","author":"T Guillaume","year":"2021","unstructured":"Guillaume T, Th\u00e9pot S, Peterlin P, Ceballos P, Bourgeois AL, Garnier A, et al. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplant Cell Ther. 2021;27:839.e1\u2013839.e6.","journal-title":"Transplant Cell Ther"},{"key":"2709_CR37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024;8:978\u201390.","journal-title":"Blood Adv"},{"key":"2709_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-023-01515-4","volume":"17","author":"C Lacan","year":"2024","unstructured":"Lacan C, Lambert J, Forcade E, Robin M, Chevallier P, Loron S, et al. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry. J Hematol Oncol. 2024;17:2.","journal-title":"J Hematol Oncol"},{"key":"2709_CR39","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/s41409-022-01816-1","volume":"57","author":"A Spyridonidis","year":"2022","unstructured":"Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G, et al. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2022;57:1774\u201380.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR40","doi-asserted-by":"crossref","unstructured":"Ciceri F, Bacigalupo A, Lankester A, Bertaina A Haploidentical HSCT. In: Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (eds). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer: Cham (CH), 2019 http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553970\/ (accessed 4 Mar2024).","DOI":"10.1007\/978-3-030-02278-5_65"},{"key":"2709_CR41","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02709-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:09:07Z","timestamp":1764662947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02709-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02709-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the SFGM-TC. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}]}}